NIH
KEI Comments Regarding NIH Exclusive License to TeraImmune for T Cell Therapy
(UPDATE: The NIH provided a response to our comments on February 25, 2020) On February 3, 2020, Knowledge Ecology International (KEI) submitted comments to the “Prospective Grant of Exclusive Patent License: Development of Regulatory T-Cell Therapies for the Treatment of… Continue Reading
KEI Comments Regarding NIH Exclusive License on Gene Therapy to Treat Ocular Disease
On Friday January 10, 2020, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: Gene Therapy for Ocular Disease” to OcQuila Therapeutics, Ltd. (84 FR 65169). The… Continue Reading
KEI Requests the NIH to Investigate Failure to Disclose Federal Funding in Opdivo and Keytruda Patents
On December 20, 2019, Knowledge Ecology International (KEI) filed a request to the National Institutes of Health (NIH) that it investigate an apparent failure to disclose federal funding in patents associated with cancer immunotherapies Opdivo and Keytruda. A court case… Continue Reading
KEI, UACT, Public Citizen, SSW, LWC Health Appeal NIH Grant of Exclusive License on Gene Therapy for Cancer to Intima Biosciences
On October 26, 2019, Knowledge Ecology International (KEI), Union for Affordable Cancer Treatment (UACT), Public Citizen, Social Security Works (SSW), LWC Health, Ruth Lopert, Manon Ress, and Terry Love filed an administrative appeal with the National Institutes of Health (NIH).… Continue Reading
KEI and UACT Comments Regarding NIH Exclusive License on GPC3-Expressing Cancer Treatment
On Tuesday November 12, 2019, KEI and the Union for Affordable Cancer Treatment (UACT) filed comments on the National Institutes of Health’s (NIH) “Prospective Grant of an Exclusive Patent License: The Development of an Anti-GPC3 Radionuclide Immunoconjugate for the Treatment… Continue Reading
KEI Comments to the NIH on Exclusive License to Opsis Therapeutics for Retinal Cell Therapies
On October 18, 2019, Knowledge Ecology International (KEI) submitted comments to the Federal Register Notice for the “Prospective Grant of an Exclusive Patent License: Compositions, Devices and Processes for Production and Delivery of Cell Grafts of Manufactured Retinal Pigment Epithelium… Continue Reading
KEI and UACT Comments to NIH on License to T-Cell Therapy for Cancer to Ziopharm Oncology
(Update: The NIH provided a response to our comments on November 15, 2019) On Friday October 18, 2019, Knowledge Ecology International and the Union for Affordable Cancer Treatment (UACT) submitted comments on the “Prospective Grant of an Exclusive Patent License:… Continue Reading
KEI and UACT Comments to NIH on License in AAV Vectors to Generation Bio and Spark Therapeutics
On Friday October 11, 2019, Knowledge Ecology International and the Union for Affordable Cancer Treatment (UACT) submitted comments to the Federal Register notice (84 FR 51171) for the “Prospective Grant of Exclusive Patent License: Capsid-Free AAV Vectors, Compositions, and Methods… Continue Reading
Joint Comments by KEI, UACT, Social Security Watch and Health Gap on the proposed NIH Exclusive License in CAR Therapy to Lyell Immunopharma (and NIH Response)
(UPDATE: As noted in the comments below, the NIH provided a response to the joint comments submitted on September 5, 2019, well in advance of the close of the comment period on September 15, 2019) On September 19, 2019, Knowledge… Continue Reading